home / stock / nxtc / nxtc news

NXTC News and Press, NextCure Inc. From 08/03/23

Stock Information
Company Name: NextCure Inc.
Stock Symbol: NXTC
Market: NYSE
Website: nextcure.com
Menu
NXTC NXTC Quote NXTC Short NXTC News NXTC Articles NXTC Message Board
Get NXTC Alerts

News, Short Squeeze, Breakout and More Instantly...
NXTC - NextCure GAAP EPS of -$0.64 misses by $0.05

2023-08-03 17:43:36 ET NextCure press release ( NASDAQ: NXTC ): Q2 GAAP EPS of -$0.64 misses by $0.05 . Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million as compared to $159.9 million as of December 31, 2022. The decrease of $29...
NXTC - NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023 Cash of approximately $131 million expected to fund operations into mid-2025 BELTSVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinic...

NXTC - NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of a p...

NXTC - NextCure GAAP EPS of -$0.58 beats by $0.04

2023-05-04 17:56:06 ET NextCure press release ( NASDAQ: NXTC ): Q1 GAAP EPS of -$0.58 beats by $0.04 . Cash, cash equivalents, and marketable securities as of March 31, 2023, were $145.5 million as compared to $159.9 million as of December 31, 2022. The decrease of $14...
NXTC - NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) Cash of approximately $145 million expected to fund operations into mid-2025 BELTSVILLE, Md., May 04...

NXTC - NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present a...

NXTC - NextCure GAAP EPS of -$2.69 misses by $0.04

NextCure press release ( NASDAQ: NXTC ): FY GAAP EPS of -$2.69 misses by $0.04 . Cash, cash equivalents, and marketable securities as of December 31, 2022, were $159.9 million as compared to $219.6 million as of December 31, 2021. NextCure expects its existing cash, c...
NXTC - NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Clinical data updates expected in 2023 for all three programs NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML) Ended 2022 with approximately $160 million in cash that is expected to fund operations into mid-2025 BELTSVILLE, Md.,...

NXTC - NextCure to Present at SVB Securities Global Biopharma Conference

BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at...

NXTC - NextCure to Present at Upcoming Investor Conferences

BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pres...
Previous 10 Next 10